SAB Biotherapeutics, Inc.

NasdaqCM:SABS Stock Report

Market Cap: US$188.0m

SAB Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SABS?
Owner TypeNumber of SharesOwnership Percentage
Private Companies54,7690.115%
Individual Insiders1,888,2893.97%
Institutions5,227,25011%
Hedge Funds7,252,38115.2%
VC/PE Firms15,821,50033.2%
General Public17,362,66236.5%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 415.8%.

Top Shareholders

Top 25 shareholders own 63.26% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
24%
Vivo Capital, LLC
11,420,000US$45.1m0%2.25%
9.25%
RA Capital Management, L.P.
4,401,500US$17.4m0%0.16%
9.25%
Commodore Capital LP
4,401,500US$17.4m0%0.6%
5.99%
Woodline Partners LP
2,850,881US$11.3m0%0.05%
4.62%
Sessa Capital IM, L.P.
2,198,457US$8.7m380%0.19%
1.96%
BVF Partners L.P.
932,697US$3.7m1.62%0.1%
1.19%
Sphera Funds Management Ltd
566,395US$2.2m0%0.32%
1.1%
Eddie Sullivan
523,230US$2.1m0%no data
1.05%
Christine Hamilton
501,808US$2.0m0%no data
0.96%
Andrew Moin
458,457US$1.8m0%no data
0.77%
The Vanguard Group, Inc.
365,753US$1.4m29.5%no data
0.65%
Edward Hamilton
308,325US$1.2m0%no data
0.65%
HB Wealth Management, LLC
307,500US$1.2m0%0.01%
0.42%
AWM Investment Company Inc
200,000US$790.0k0%0.08%
0.35%
Simplify Asset Management Inc.
168,227US$664.5k0%0.01%
0.23%
Janus Henderson Group plc
107,757US$425.6k0%no data
0.18%
Geode Capital Management, LLC
85,718US$338.6k1.12%no data
0.17%
Renaissance Technologies LLC
80,840US$319.3k633%no data
0.12%
Big Cypress Holdings LLC
54,769US$216.3k0%no data
0.11%
Pathstone Family Office, LLC
50,650US$200.1k0%no data
0.083%
Jeffrey Spragens
39,498US$156.0k0%no data
0.062%
Alexandra Kropotova
29,340US$115.9k21.6%no data
0.046%
Samuel Reich
21,900US$86.5k0%no data
0.042%
Virtu Financial, Inc.
19,982US$78.9k0%no data
0.04%
Kovitz Investment Group Partners, LLC
19,201US$75.8k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/01 03:45
End of Day Share Price 2025/11/28 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SAB Biotherapeutics, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Keay NakaeChardan Capital Markets, LLC
Gum-Ming LoweCraig-Hallum Capital Group LLC